Abstract
In recent years, there is a growing interest in research to investigate the importance of gut microbiome in health and diseases. This opens a new area of research for the role of microbial flora of the human gut in inflammation, energy homeostasis, pathogenesis of obesity and other associated disorders. Recent studies propose association of the gut microbiome with development of obesity and metabolic syndromes, such as type 2 diabetes mellitus (T2DM). The T2DM is a metabolic disease that is mainly caused by obesity-linked insulin resistance. The vascular effects of obesity appears to play a role in the development of Alzheimer’s disease (AD) that is one of the rapidly growing diseases of a late stage of life all over the world. Studies from both humans and mice models have been demonstrated the engagement of gut microbial flora in the pathogenesis of obesity and host metabolism. The aim of this review is to discuss the current findings that may explain the cascade of gut microbial flora participation in the development of obesity, T2DM and further initiation of AD. In addition, the available data regarding the mechanisms that have been proposed to elucidate the role of gut microbiota in weight gain and possible cause of T2DM and AD have been examined.
Keywords: Gut microbiota, obesity, metabolic disease, type 2 diabetes mellitus, Alzheimer’s disease.
CNS & Neurological Disorders - Drug Targets
Title:Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
Volume: 13 Issue: 2
Author(s): Muhammad I. Naseer, Fehmida Bibi, Mohammed H. Alqahtani, Adeel G. Chaudhary, Esam I. Azhar, Mohammad A. Kamal and Muhammad Yasir
Affiliation:
Keywords: Gut microbiota, obesity, metabolic disease, type 2 diabetes mellitus, Alzheimer’s disease.
Abstract: In recent years, there is a growing interest in research to investigate the importance of gut microbiome in health and diseases. This opens a new area of research for the role of microbial flora of the human gut in inflammation, energy homeostasis, pathogenesis of obesity and other associated disorders. Recent studies propose association of the gut microbiome with development of obesity and metabolic syndromes, such as type 2 diabetes mellitus (T2DM). The T2DM is a metabolic disease that is mainly caused by obesity-linked insulin resistance. The vascular effects of obesity appears to play a role in the development of Alzheimer’s disease (AD) that is one of the rapidly growing diseases of a late stage of life all over the world. Studies from both humans and mice models have been demonstrated the engagement of gut microbial flora in the pathogenesis of obesity and host metabolism. The aim of this review is to discuss the current findings that may explain the cascade of gut microbial flora participation in the development of obesity, T2DM and further initiation of AD. In addition, the available data regarding the mechanisms that have been proposed to elucidate the role of gut microbiota in weight gain and possible cause of T2DM and AD have been examined.
Export Options
About this article
Cite this article as:
Naseer I. Muhammad, Bibi Fehmida, Alqahtani H. Mohammed, Chaudhary G. Adeel, Azhar I. Esam, Kamal A. Mohammad and Yasir Muhammad, Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (2) . https://dx.doi.org/10.2174/18715273113126660147
DOI https://dx.doi.org/10.2174/18715273113126660147 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Midkine in Inflammatory and Toxic Conditions
Current Drug Delivery Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Astrocytic Expression of the Immunoreceptor CD300f Protects Hippocampal Neurons from Amyloid-β Oligomer Toxicity In Vitro
Current Alzheimer Research Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Borna Disease Virus (BDV): Neuropharmacological Effects of a CNS Viral Infection
Current Neuropharmacology The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design The Pro-Apoptotic Substance Thapsigargin Selectively Stimulates Re-Growth of Brain Capillaries
Current Neurovascular Research Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Upregulation of Suppressor of Cytokine Signaling 3 in Microglia by Cinnamic Acid
Current Alzheimer Research Physiology and Therapeutic Potential of the Thymic Peptide Thymulin
Current Pharmaceutical Design Extraction, Characterization and In Vivo Neuromodulatory Activity of Phytosterols from Microalga Dunaliella Tertiolecta
Current Medicinal Chemistry Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases
Current Pharmaceutical Design Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Connexins and Pannexins in Ischemic Stroke
Current Medicinal Chemistry Therapeutic Interventions of Tissue Specific Autoimmune Onset in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry